Coronado Seeks Partner To Support PNT Glaucoma Device Regulatory Process
This article was originally published in The Gray Sheet
Executive Summary
Coronado Industries is negotiating with several firms for U.S. distribution of its PNT (pneumatic trabeculoplasty) system for open-angle and pigmentary glaucoma, as well as hypertension, the firm says
You may also be interested in...
Novartis Will Bundle Coronado's PNT Glaucoma Device With Rescula Drops
Novartis Ophthalmics' exclusive licensing and distribution agreement with Coronado Industries will allow the company to offer ophthalmologists Coronado's PNT (pneumatic trabeculoplasty) suction device for primary treatment of glaucoma along with its own Rescula glaucoma drops.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.